5-LOXIN®

Shows Improvement in Joint Comfort and Flexibility within 7 days!
Benifit Image
7 days
5-LOXIN has been shown in clinical trials to improve joint comfort in as little as 7 days.
Benifit Image
100mg
Proven efficacy at only 100 mg/day
Benifit Image
15 Studies
5-LOXIN is supported by 13 pre-clinical and 2 human clinical trials.
Benifit Image
100,000 trees
We work to maintain the natural resources that support 5-LOXIN – planting over 100,000 Boswellia trees in the last 2 years

Make Every Day Independence Day.

Joint discomfort can rob a person of their ability to do the simple things in everyday life. Every moment’s loss of mobility seems like an eternity.

With 5-LOXIN, you can help your customers get their freedom to move back faster. Clinical studies have shown that a small 100 mg dose of 5-LOXIN reduces joint discomfort and enhances flexibility in as little as 7 days.

Around the world, people have turned to 5-LOXIN as a drug-free approach to joint comfort. They trust the science. Trust the quality. And trust the experience.

Key Features
  • Boswellic acids are natural, selective 5-lipoxygenase inhibitors. 3-O-acetyl-11-keto-ß-boswellic acid or “AKBA” is the most active.
  • 5-LOXIN® provides a higher concentration of AKBA, standardized to 30%.
  • In a human study, both 100mg and 250mg of 5-LOXIN® daily provided improvement in joint comfort and mobility within 7 days.
  • 5-LOXIN® provided significant benefits in WOMAC, VAS and LFI standardized testing methodologies for joint health.
  • 5-LOXIN® positively impacted biological markers associated with joint and general health, including TNFa, CRP, and IL-6.
  • 5-LOXIN® was shown to significantly inhibit matrix metalloproteinase (MMP-3), enzymes that break down cartilage, collagen and connective tissues.
  • 5-LOXIN® is well-tolerated, easy on the stomach and supported by extensive safety data

Active/Sports Nutrition

5-LOXIN can be an important part of your active/sports nutrition formulations. Inflammation from exercise has similarities to the type of inflammation that occurs with the aging process. 5-LOXIN can help you get your customers back into the gym faster.

Back view of strong sporty girl showing muscles at the beach during sunset.
Runner Warming Up Before Running

Bone, Joint & Muscle Health

5-LOXIN is one of the world’s best-selling joint health ingredients – with multiple clinical studies that demonstrate efficacy starting at 7 days – with a low dose.

Healthy Aging

Today’s seniors travel more, play more and do more than ever. 5-LOXIN can help them get moving and keep moving. They’ll notice the difference quickly and come back for more.

Grandparents And Granddaughter Walking On Winter Beach
Close Up Of Woman Standing On Bathroom Scales At Home

Weight Management

Mobility and freedom from discomfort are critical to the kind of exercise we need to maintain a healthy weight. 5-LOXIN can help your customers succeed in achieving their weight management goals by giving them the freedom to workout.

Good For
Ingredient Solutions
Bone, Joint & Muscle
Healthy Aging
Active Nutrition
Applications
Capsules
Tablets
Powders
Stick Packs
Effervescents
Research

Fifteen Studies and Counting

5-LOXIN is a novel Boswellia serrata extract enriched with 30% 3-O-acetyl-11-keto-beta-boswellic acid (AKBA), which exhibits potential anti-inflammatory properties by inhibiting the 5-lipoxygenase enzyme. In joint health products, it is used both as a standalone ingredient and in conjunction with other ingredients to power some of the best-known joint health consumer brands in the world.

5-LOXIN has been the subject of 13 pre-clinical studies and 2 human clinical trials. One of the key features of 5-LOXIN in any formulation is clinical work that has demonstrated efficacy starting at 7 days – at a significantly lower dose (100 mg) than other joint health ingredients. This fast efficacy and low dose allow 5-LOXIN to compete with non-natural or over-the-counter solutions.

Beyond joint comfort and flexibility improvements, 5-LOXIN also positively impacts biological markers associated with joint health and inflammation, including TNFa, CRP, and IL-6. It was also shown to significantly inhibit matrix metalloproteinase (MMP-3), enzymes that break down cartilage, collagen and connective tissues.

Results:

 

 

INSIGHTS

5-LOXIN is derived from Boswellia serrata gum resin and contains 30% AKBA. It was the first entrant into PLT’s global portfolio of AKBA-based joint health ingredients.

The starting point for 5-LOXIN – Boswellia serrata – is a plant that produces Indian frankincense. It is also known as Indian oli-banum, Salai guggul, and Sallaki in Sanskrit.  The plant is native to much of India and the Punjab region that extends into Pakistan. In the last five years, PLT partner Laila Nutra has planted over 10,000 frankincense trees in India. Laila and PLT are committed to the safety and fair treatment of the people who harvest 5-LOXIN. We want to support the long-term health and well-being of the tribal culture and the natural environment upon which it relies.

Every batch of the 5-LOXIN harvest is assigned a specific batch number and each batch of finished product is traceable to specific region and set of trees. 5-LOXIN is tested and must comply with predefined specifications for different parameters at different stages of product manufacturing – from raw materials to finished product. Quality is monitored by a multi-disciplinary organization with dedicated departments for taxonomy (botanical Identification), raw material analysis, chemical analysis, microbiology and more.

Resources
Selected Published Research with 5-LOXIN®
Human genome screen to identify the genetic basis of the anti-inflammatory effects of Boswellia in microvascular endothelial cells.
Roy S, Khanna S, Shah H, Rink C, Phillips C, Preuss H, Subbaraju GV, Trimurtulu G, Krishnaraju AV, Bagchi M, Bagchi D, Sen CK. DNA Cell Biol. 2005; 24: 244-55.
View PDF
Inducible matrix metalloproteinase-3 expression in human microvascular endothelial cells is sensitive to anti-inflammatory Boswellia.
Roy S, Khanna S, Krishnaraju AV, Subbaraju GV, Yasmin T, Bagchi M, Sen CK. Antioxidants & Redox Signaling, 8, 3 & 4, 2006.
View PDF
Safety and toxicological evaluation of a novel, standardized 3-acetyl-11-keto-beta-boswellic acid (AKBA)-enriched Boswellia serrata extract (5-LOXIN®).
Lalithakumari K, Krishnaraju AV, Subbaraju GV, Yasmin T, Chatterjee A. Toxicology Mechanisms and Methods 16: 199–226, 2006.
View PDF
A double-blind, randomized, placebo controlled study of the efficacy and safety of 5-LOXIN® for treatment of osteoarthritis of the knee.
Krishanu Sengupta, Krishnaraju V Alluri, Andey Rama Satish, Simanchala Mishra, Trimurtulu Golakoti, Kadainti VS Sarma, Dipak Dey and Siba P Raychaudhuri. Arthritis Research & Therapy, Vol 10 (4): R85, 2008.
View PDF
Selected 5-LOXIN® Press Releases
Human Study Demonstrates Joint Comfort and Mobility in 7 Days
5-LOXIN® proven to reduce the symptoms of osteoarthritis in new human study published in Arthritis Research and Therapy.
View PDF
Review Article on Boswellia Serrata Highlights 5-LOXIN®'s Efficacy
Frankincense Provides Relief for Osteoarthritis; New Article in BMJ - British Medical Journal December Issue
View PDF
5-LOXIN® and Human Gene Expression Demonstrate Mechanism
New study of Human Genome Screen Shows Basis of 5-LOXIN’s Anti-inflammatory Effects
View PDF
Study with 5-LOXIN® and MMP Enzymes Shows Protective Benefit
New Study shows 5-LOXIN® AKBA to Inhibit inflammation and tissue breakdown in vitro and in vivo
View PDF
5-LOXIN® Safety Demonstrated in Oral, Topical and Toxicity Testing
New Study Confirms Safety of 5-LOXIN® AKBA, a natural anti-inflammatory
View PDF
PLT and Laila Nutraceuticals Announce Alliance
P.L. Thomas and Laila Impex Announce Strategic Alliance
View PDF

Ready to realize your product’s full potential?

We work closely with our customers and our world-wide suppliers to source and scientifically back innovative ingredients for your product development needs.